U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Poorly differentiated thyroid gland carcinoma

MedGen UID:
266094
•Concept ID:
C1266050
•
Neoplastic Process
Synonyms: Insular carcinoma; Insular Carcinoma; insular carcinoma; Poorly Differentiated Carcinoma of the Thyroid Gland; poorly differentiated carcinoma of the thyroid gland; Poorly Differentiated Carcinoma of Thyroid Gland; poorly differentiated carcinoma of thyroid gland; poorly differentiated thyroid cancer; Poorly Differentiated Thyroid Carcinoma; poorly differentiated thyroid carcinoma; poorly differentiated thyroid gland cancer; Poorly Differentiated Thyroid Gland Carcinoma; poorly differentiated thyroid gland carcinoma; Thyroid Gland Poorly Differentiated Carcinoma; thyroid gland poorly differentiated carcinoma
SNOMED CT: Insular carcinoma (128673009)
 
Monarch Initiative: MONDO:0006382

Definition

A follicular-derived thyroid gland carcinoma that is histologically poorly differentiated and has high-grade features. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPoorly differentiated thyroid gland carcinoma

Professional guidelines

PubMed

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O
Thyroid 2021 Jul;31(7):1076-1085. Epub 2021 Apr 15 doi: 10.1089/thy.2020.0322. PMID: 33509020Free PMC Article
Thyroid pathology: Controversies and best practices.
Nishino M
Semin Diagn Pathol 2020 Sep;37(5):211-212. Epub 2020 Aug 5 doi: 10.1053/j.semdp.2020.07.004. PMID: 32782166
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL
J Thorac Oncol 2019 Mar;14(3):377-407. Epub 2018 Dec 18 doi: 10.1016/j.jtho.2018.12.005. PMID: 30572031Free PMC Article

Recent clinical studies

Etiology

Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading.
Christofer Juhlin C, Mete O, Baloch ZW
Endocr Relat Cancer 2023 Feb 1;30(2) Epub 2022 Dec 22 doi: 10.1530/ERC-22-0293. PMID: 36445235
Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O
Thyroid 2021 Jul;31(7):1076-1085. Epub 2021 Apr 15 doi: 10.1089/thy.2020.0322. PMID: 33509020Free PMC Article
Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M
Front Endocrinol (Lausanne) 2020;11:102. Epub 2020 Mar 13 doi: 10.3389/fendo.2020.00102. PMID: 32231639Free PMC Article

Diagnosis

Oncocytic Poorly Differentiated Thyroid Carcinoma.
Whaley RD, Gupta S, Erickson LA
Mayo Clin Proc 2024 Mar;99(3):511-512. doi: 10.1016/j.mayocp.2023.11.002. PMID: 38432755
Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading.
Christofer Juhlin C, Mete O, Baloch ZW
Endocr Relat Cancer 2023 Feb 1;30(2) Epub 2022 Dec 22 doi: 10.1530/ERC-22-0293. PMID: 36445235
Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M
Front Endocrinol (Lausanne) 2020;11:102. Epub 2020 Mar 13 doi: 10.3389/fendo.2020.00102. PMID: 32231639Free PMC Article

Therapy

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.
Jeon Y, Park S, Lee SH, Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH
Cancer Res Treat 2024 Oct;56(4):1270-1276. Epub 2024 Mar 6 doi: 10.4143/crt.2023.1278. PMID: 38453274Free PMC Article
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME
JAMA Oncol 2023 Aug 1;9(8):1132-1141. doi: 10.1001/jamaoncol.2023.1379. PMID: 37289450
Perspective: The Molecular Landscape of Radioactive Iodine Refractory Differentiated Thyroid Cancer and Poorly Differentiated Thyroid Cancer.
Shobab L, Wartofsky L
Thyroid 2023 Feb;33(2):138-142. Epub 2022 Nov 30 doi: 10.1089/thy.2022.0428. PMID: 36345225
Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration.
Sun YQ, Sun D, Zhang X, Zhang YQ, Lin YS
Front Endocrinol (Lausanne) 2022;13:994288. Epub 2022 Nov 30 doi: 10.3389/fendo.2022.994288. PMID: 36531486Free PMC Article
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O
Thyroid 2021 Jul;31(7):1076-1085. Epub 2021 Apr 15 doi: 10.1089/thy.2020.0322. PMID: 33509020Free PMC Article

Prognosis

The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading.
Christofer Juhlin C, Mete O, Baloch ZW
Endocr Relat Cancer 2023 Feb 1;30(2) Epub 2022 Dec 22 doi: 10.1530/ERC-22-0293. PMID: 36445235
Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O
Endocr Pathol 2022 Mar;33(1):27-63. Epub 2022 Mar 14 doi: 10.1007/s12022-022-09707-3. PMID: 35288841
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O
Thyroid 2021 Jul;31(7):1076-1085. Epub 2021 Apr 15 doi: 10.1089/thy.2020.0322. PMID: 33509020Free PMC Article
Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M
Front Endocrinol (Lausanne) 2020;11:102. Epub 2020 Mar 13 doi: 10.3389/fendo.2020.00102. PMID: 32231639Free PMC Article
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
Ibrahimpasic T, Ghossein R, Shah JP, Ganly I
Thyroid 2019 Mar;29(3):311-321. doi: 10.1089/thy.2018.0509. PMID: 30747050Free PMC Article

Clinical prediction guides

Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome.
Liu D, Yehia L, Dhawan A, Ni Y, Eng C
Cell Rep Med 2024 Feb 20;5(2):101384. Epub 2024 Jan 18 doi: 10.1016/j.xcrm.2023.101384. PMID: 38242121Free PMC Article
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O
Thyroid 2021 Jul;31(7):1076-1085. Epub 2021 Apr 15 doi: 10.1089/thy.2020.0322. PMID: 33509020Free PMC Article
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
Ibrahimpasic T, Ghossein R, Shah JP, Ganly I
Thyroid 2019 Mar;29(3):311-321. doi: 10.1089/thy.2018.0509. PMID: 30747050Free PMC Article
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA
J Clin Invest 2016 Mar 1;126(3):1052-66. Epub 2016 Feb 15 doi: 10.1172/JCI85271. PMID: 26878173Free PMC Article

Recent systematic reviews

Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Kim JY, Myung JK, Kim S, Tae K, Choi YY, Lee SJ
Endocrinol Metab (Seoul) 2024 Aug;39(4):590-602. Epub 2024 Jun 27 doi: 10.3803/EnM.2024.1927. PMID: 38925909Free PMC Article
Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.
Chatterjee S, Mair M, Shaha AR, Paleri V, Sawhney S, Mishra A, Bhandarkar S, D'Cruz AK
Endocrine 2024 Aug;85(2):509-519. Epub 2024 Mar 19 doi: 10.1007/s12020-024-03771-x. PMID: 38504051
Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.
Coca-Pelaz A, Rodrigo JP, Agaimy A, Williams MD, Saba NF, Nuyts S, Randolph GW, López F, Vander Poorten V, Kowalski LP, Civantos FJ, Zafereo ME, Mäkitie AA, Cohen O, Nixon IJ, Rinaldo A, Ferlito A
Virchows Arch 2024 May;484(5):733-742. Epub 2024 Feb 24 doi: 10.1007/s00428-024-03752-5. PMID: 38400843
Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis.
Poma AM, Macerola E, Ghossein RA, Tallini G, Basolo F
Thyroid 2024 Mar;34(3):314-323. doi: 10.1089/thy.2023.0350. PMID: 38115626Free PMC Article
Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P, Giovanella L
Clin Chem Lab Med 2015 Sep 1;53(10):1507-14. doi: 10.1515/cclm-2015-0058. PMID: 25781697

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...